Literature DB >> 10026187

Anticoagulant heparan sulfate precursor structures in F9 embryonal carcinoma cells.

L Zhang1, K Yoshida, J Liu, R D Rosenberg.   

Abstract

To understand the mechanisms that control anticoagulant heparan sulfate (HSact) biosynthesis, we previously showed that HSact production in the F9 system is determined by the abundance of 3-O-sulfotransferase-1 as well as the size of the HSact precursor pool. In this study, HSact precursor structures have been studied by characterizing [6-3H]GlcN metabolically labeled F9 HS tagged with 3-O-sulfates in vitro by 3'-phosphoadenosine 5'-phospho-35S and purified 3-O-sulfotransferase-1. This later in vitro labeling allows the regions of HS destined to become the antithrombin (AT)-binding sites to be tagged for subsequent structural studies. It was shown that six 3-O-sulfation sites exist per HSact precursor chain. At least five out of six 3-O-sulfate-tagged oligosaccharides in HSact precursors bind AT, whereas none of 3-O-sulfate-tagged oligosaccharides from HSinact precursors bind AT. When treated with low pH nitrous or heparitinase, 3-O-sulfate-tagged HSact and HSinact precursors exhibit clearly different structural features. 3-O-Sulfate-tagged HSact hexasaccharides were AT affinity purified and sequenced by chemical and enzymatic degradations. The 3-O-sulfate-tagged HSact hexasaccharides exhibited the following structures, DeltaUA-[6-3H]GlcNAc6S-GlcUA-[6-3H]GlcNS3(35)S+/-6S-++ +IdceA2S-[6-3H]Glc NS6S. The underlined 6- and 3-O-sulfates constitute the most critical groups for AT binding in view of the fact that the precursor hexasaccharides possess all the elements for AT binding except for the 3-O-sulfate moiety. The presence of five potential AT-binding precursor hexasaccharides in all HSact precursor chains demonstrates for the first time the processive assembly of specific sequence in HS. The difference in structures around potential 3-O-sulfate acceptor sites in HSact and HSinact precursors suggests that these precursors might be generated by different concerted assembly mechanisms in the same cell. This study permits us to understand better the nature of the HS biosynthetic pathway that leads to the generation of specific saccharide sequences.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10026187     DOI: 10.1074/jbc.274.9.5681

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Screening for anticoagulant heparan sulfate octasaccharides and fine structure characterization using tandem mass spectrometry.

Authors:  Hicham Naimy; Nancy Leymarie; Joseph Zaia
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

2.  Directing the biological activities of heparan sulfate oligosaccharides using a chemoenzymatic approach.

Authors:  Yongmei Xu; Zhen Wang; Renpeng Liu; Arlene S Bridges; Xuefei Huang; Jian Liu
Journal:  Glycobiology       Date:  2011-08-11       Impact factor: 4.313

3.  Glycosaminoglycans in Human and Bovine Serum: Detection of Twenty-Four Heparan Sulfate and Chondroitin Sulfate Motifs Including a Novel Sialic Acid-modified Chondroitin Sulfate Linkage Hexasaccharide.

Authors:  Hong Lu; Lynda M McDowell; Daniel R Studelska; Lijuan Zhang
Journal:  Glycobiol Insights       Date:  2010-02-09

4.  Modification degrees at specific sites on heparan sulphate: an approach to measure chemical modifications on biological molecules with stable isotope labelling.

Authors:  Zhengliang L Wu; Miroslaw Lech
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

Review 5.  Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes.

Authors:  Nicholas W Shworak; Sassan HajMohammadi; Ariane I de Agostini; Robert D Rosenberg
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

6.  Human follicular fluid heparan sulfate contains abundant 3-O-sulfated chains with anticoagulant activity.

Authors:  Ariane I de Agostini; Ji-Cui Dong; Corinne de Vantéry Arrighi; Marie-Andrée Ramus; Isabelle Dentand-Quadri; Sébastien Thalmann; Patricia Ventura; Victoria Ibecheole; Felicia Monge; Anne-Marie Fischer; Sassan HajMohammadi; Nicholas W Shworak; Lijuan Zhang; Zhenqing Zhang; Robert J Linhardt
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

Review 7.  Heparan sulfate 3-O-sulfation: a rare modification in search of a function.

Authors:  Bryan E Thacker; Ding Xu; Roger Lawrence; Jeffrey D Esko
Journal:  Matrix Biol       Date:  2013-12-19       Impact factor: 11.583

8.  Modification of plasma glycosaminoglycans in long distance runners.

Authors:  M Contini; S Pacini; L Ibba-Manneschi; V Boddi; M Ruggiero; G Liguri; M Gulisano; C Catini
Journal:  Br J Sports Med       Date:  2004-04       Impact factor: 13.800

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.